<DOC>
	<DOCNO>NCT03013322</DOCNO>
	<brief_summary>Anticholium® per Se randomize , double-blind , placebo-controlled , monocentric trial ass whether CAP transfer bench bedside . In pilot study , 20 patient perioperative sepsis septic shock result intra-abdominal infection enrol . According randomization , participant treat physostigmine salicylate ( verum group ) 0.9 % sodium chloride ( placebo group ) 5 day . The mean Sequential Organ Failure Assessment ( SOFA ) score treatment subsequent intensive care 14 day use surrogate outcome ( primary endpoint ) . Secondary outcome measure include 30- 90-day mortality . An embedded pharmacokinetics pharmacodynamics study investigates plasma concentration physostigmine metabolite eseroline . Further analysis contribute understanding role various cytokine pathophysiology human sepsis . A computer-generated list use blocked randomization .</brief_summary>
	<brief_title>Anticholium® Per Se</brief_title>
	<detailed_description />
	<mesh_term>Shock</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Physostigmine</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<criteria>Inclusion criterion Age 1885 year APACHE II score &lt; 34 Intraabdominal infection finding diffuse peritonitis circumscribed abscess Perioperative sepsis secure evidence infection , clinically back secure microbiologically ≥2 follow four criterion : fever ≥38.0° C hypothermia ≤36.0° C secure rectal intravesical intravascular measurement tachycardia ≥90/min tachypnea ≥20/min hyperventilation secure arterial blood gas analysis PaCO2 ≤4.3 kPa 33 mmHg mechanical artificial respiration leukocytosis ≥12,000/mm³ leukopenia ≤4000/mm³ ≥10 % immature neutrophils differential count Shock ( &lt; 24 h duration ) : necessary use vasopressor despite adequate fluid resuscitation keep systolic blood pressure ≥90 mmHg mean blood pressure ≥70 mmHg No one plan and/or one emergency basis/as emergency procedure perform since admission ( repeated revision ) No infaust prognosis primary concomitant illness , expect death within followup phase No donotresuscitate order Written inform consent fullage patients/their legal guardian participate [ write consent ( accord AMG § 40 ( 1 ) 3b ) ] unable consent adult [ § 41 ( 1 ) 2 AMG ) ] Exclusion criterion Known hypersensitivity physostigmine salicylate , sodium metabisulfite , sodium EDTA , ingredient Anticholium® Known contraindication Anticholium® : gangrene , coronary artery disease Known absolute contraindication Anticholium® : myotonic dystrophy ; depolarization block depolarize muscle relaxant ; intoxication `` irreversibly act '' cholinesterase inhibitor ; close craniocerebral trauma ; obstruction gastrointestinal tract ( mechanical constipation ) ; obstruction urinary tract ( mechanical urinary retention ) Known relative contraindication Anticholium® : bronchial asthma ; bradycardia ; AVconduction disturbances Having undergone splenectomy Having undergone solid organ transplantation Positive pregnancy test , pregnancy , lactation Participation another clinical trial , accord AMG followup phase another study , accord AMG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>